Synairgen plc (AIM: SNG)

Market Cap	18.97M
Revenue (ttm)	n/a
Net Income (ttm)	-6.92M
Shares Out	1.10B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,969,581
Average Volume	2,349,914
Open	1.865
Previous Close	2.000
Day's Range	1.713 - 2.200
52-Week Range	1.713 - 10.000
Beta	-2.21
RSI	36.30
Earnings Date	Dec 27, 2024

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SNG